Lijuan Li1, Shaohua Song1, Xiaoling Fang1, Donglin Cao2. 1. Department of Laboratory Medicine, Guangdong Second Provincial General Hospital, No. 466 Xingang Middle Road, Haizhu District, Guangzhou, 510317, Guangdong Province, China. 2. Department of Laboratory Medicine, Guangdong Second Provincial General Hospital, No. 466 Xingang Middle Road, Haizhu District, Guangzhou, 510317, Guangdong Province, China. caodl@126.com.
Abstract
BACKGROUND: The abnormal expression of activating transcription factor 3 (ATF3), a member of the basic leucine zipper (bZIP) family of transcription factors, is associated with carcinogenesis. However, the expression pattern and exact role of ATF3 in the development and progression of hepatocellular carcinoma (HCC) remain unclear. METHODS: We used UALCAN, ONCOMINE, Kaplan-Meier plotter, and cBioPortal databases to investigate the prognostic value of ATF3 expression in HCC. RESULTS: ATF3 was found to be expressed at low levels in multiple HCC tumor tissues. Moreover, low ATF3 expression was significantly associated with clinical cancer stage and pathological tumor grade in patients with HCC. Therefore, low expression of ATF3 was significantly associated with poor overall survival in patients with HCC. Functional network analysis showed that ATF3 regulates cytokine receptors and signaling pathways via various cancer-related kinases, miRNAs, and transcription factors. ATF3 expression was found to be correlated with macrophage infiltration levels and with macrophage immune marker sets in HCC patients. CONCLUSIONS: Using data mining methods, we clarified the role of ATF3 expression and related regulatory networks in HCC, laying a foundation for further functional research. Future research will validate our findings and establish clinical applications of ATF3 in the diagnosis and treatment of HCC.
BACKGROUND: The abnormal expression of activating transcription factor 3 (ATF3), a member of the basic leucine zipper (bZIP) family of transcription factors, is associated with carcinogenesis. However, the expression pattern and exact role of ATF3 in the development and progression of hepatocellular carcinoma (HCC) remain unclear. METHODS: We used UALCAN, ONCOMINE, Kaplan-Meier plotter, and cBioPortal databases to investigate the prognostic value of ATF3 expression in HCC. RESULTS: ATF3 was found to be expressed at low levels in multiple HCC tumor tissues. Moreover, low ATF3 expression was significantly associated with clinical cancer stage and pathological tumor grade in patients with HCC. Therefore, low expression of ATF3 was significantly associated with poor overall survival in patients with HCC. Functional network analysis showed that ATF3 regulates cytokine receptors and signaling pathways via various cancer-related kinases, miRNAs, and transcription factors. ATF3 expression was found to be correlated with macrophage infiltration levels and with macrophage immune marker sets in HCC patients. CONCLUSIONS: Using data mining methods, we clarified the role of ATF3 expression and related regulatory networks in HCC, laying a foundation for further functional research. Future research will validate our findings and establish clinical applications of ATF3 in the diagnosis and treatment of HCC.
Authors: Mark Gilchrist; Vesteinn Thorsson; Bin Li; Alistair G Rust; Martin Korb; Jared C Roach; Kathleen Kennedy; Tsonwin Hai; Hamid Bolouri; Alan Aderem Journal: Nature Date: 2006-05-11 Impact factor: 49.962
Authors: Alexander J A Deutsch; Beate Rinner; Kerstin Wenzl; Martin Pichler; Katharina Troppan; Elisabeth Steinbauer; Daniela Schwarzenbacher; Sonja Reitter; Julia Feichtinger; Sascha Tierling; Andreas Prokesch; Marcel Scheideler; Anne Krogsdam; Gerhard G Thallinger; Helmut Schaider; Christine Beham-Schmid; Peter Neumeister Journal: Blood Date: 2014-02-19 Impact factor: 22.113
Authors: Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally Journal: Neoplasia Date: 2017-07-18 Impact factor: 5.715
Authors: Mahmoud Youns; Momen Askoura; Hisham A Abbas; Gouda H Attia; Ahdab N Khayyat; Reham M Goda; Ahmad J Almalki; El-Sayed Khafagy; Wael A H Hegazy Journal: Onco Targets Ther Date: 2021-06-23 Impact factor: 4.147